Sebastian Ludwig | Clinical Trials | Best Research Article Award

Published on by Top Pharmaceutical

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Assist. Prof. Dr. Sebastian Ludwig, Universität zu Köln, Germany

Dr. Sebastian Ludwig (b. 1982, Leipzig) is a distinguished gynecologist and urogynecologist, currently serving as Senior Consultant and Head of the Continence and Pelvic Floor Center at the University of Cologne. He earned his medical degree from Ruhr-University Bochum (2009) and completed his habilitation in 2023, focusing on standardization in urogynecological surgery. Dr. Ludwig is a certified clinical trial leader and expert in minimally invasive surgery. Passionate about women’s health, he plays a vital role in medical education. Married with one child, he resides in Cologne.

Publication Profile

Scopus

Education

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds a Doctor of Medicine degree (magna cum laude) and has further distinguished himself by completing his habilitation, earning the venia legendi in Gynecology and Obstetrics. 🏥 His academic journey reflects a deep commitment to medical education, clinical research, and advancing women’s healthcare. With a passion for innovation and evidence-based practice, Dr. Ludwig continues to contribute significantly to his field, shaping the future of gynecological and obstetric medicine. His dedication to both patient care and academic excellence makes him a respected figure in medical education and research. 🔬📚

Experience

Assist. Prof. Dr. Sebastian Ludwig 🏥 has advanced through the medical ranks, starting as an assistant physician and progressing to Oberarzt (senior physician) at the University of Cologne’s Women’s Clinic. His expertise and leadership extend further as the Head of the Continence and Pelvic Floor Center, where he plays a pivotal role in specialized patient care and groundbreaking research. 🔬 His dedication to women’s health, particularly in urogynecology, underscores his commitment to improving treatment outcomes and advancing medical knowledge. Through his clinical and academic contributions, Dr. Ludwig continues to shape the future of gynecological care. 👨‍⚕️📚

Awards

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds multiple prestigious certifications in clinical trials, urogynaecology, gynecological endoscopy, and medical research methodologies. 🏥🔬 These qualifications reflect his dedication to continuous professional development and adherence to the highest standards of research ethics. His expertise in cutting-edge medical techniques ensures optimal patient care and contributes to the advancement of gynecological science. 📚 His commitment to lifelong learning and innovation strengthens his role as a leading specialist in women’s health, making significant contributions to both clinical practice and academic research. 👨‍⚕️💡

Research Focus

Assist. Prof. Dr. Sebastian Ludwig is a dedicated researcher in minimally invasive gynecologic surgery 🏥🔬, with a primary focus on laparoscopic and open abdominal procedures for treating pelvic organ prolapse and related conditions. His work integrates advanced surgical techniques 🏗️, interdisciplinary approaches, and long-term patient outcomes 📊. His studies on uterine ligament replacement and colorectal-gynecological procedures contribute to improving women’s healthcare 👩‍⚕️💙. His research also explores trends in obstetrics 🤰📉, offering insights into evolving birth practices. With publications in top medical journals 📖🏆, Dr. Ludwig plays a crucial role in advancing female pelvic reconstructive surgery 🩺✨.

Publication Top Notes

Comparison of Open Abdominal and Laparoscopic Bilateral Uterosacral Ligament Replacement: A One-Year Follow-Up Study

Early safety and efficiency outcomes of a novel interdisciplinary laparoscopic resection rectopexy combined with sacrocolpopexy for women with obstructive defecation syndrome and pelvic organ prolapse: a single center study

Shifting Trends in Obstetrics: An 18-year Analysis of Low-risk Births at a German University Hospital

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Published on by Top Pharmaceutical

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Dr Hui Xiao,regeneron,United States

Dr. Hui Xiao 🧪🔬 is a distinguished scientist specializing in biochemistry, structural biology, and mass spectrometry. With a strong focus on microtubule dynamics, protein interactions, and drug mechanisms, he has made significant contributions to understanding cellular processes. As a co-first author and lead researcher, his work has been published in esteemed journals like J. Mol. Biol., Biochemistry, and J. Biol. Chem.. His expertise spans hydrogen-deuterium exchange, proteomics, and molecular stabilization studies. Dr. Xiao’s research has advanced drug discovery, particularly in cancer therapeutics and protein biochemistry. 📚🔍 His innovative approaches continue to impact biomedical sciences globally. 🌍✨

Publication Profile

Scopus

Education

Dr. Hui Xiao 🎓 holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst (2005) and a degree in Applied Chemistry from Peking University, China (1992). Currently serving as an Associate Director at Regeneron Pharmaceuticals 🏢, he specializes in protein characterization using mass spectrometry. With over a decade at Regeneron, he has progressed through roles as a Senior Staff Scientist and Staff Scientist. Previously, he held academic positions at Albert Einstein College of Medicine 🧬, advancing from Instructor to Research Associate Professor. His expertise spans analytical chemistry, protein analysis, and therapeutic protein research, making significant contributions to biomedical science. 🔬

Professional Impact

Dr. Hui Xiao 🎓 is a distinguished scientist with over 20 years of experience in academia and the biotechnology industry. Currently, he serves as an Associate Director of Analytical Chemistry at Regeneron Pharmaceuticals 🏢, a leading biotech company. His expertise lies in mass spectrometry applications for protein characterization 🔬, contributing to advancements in therapeutic development. Before joining Regeneron, Dr. Xiao held esteemed faculty positions at Albert Einstein College of Medicine 🧬, progressing from Instructor to Research Associate Professor. His extensive research and leadership have played a crucial role in bridging analytical chemistry with biopharmaceutical innovation, impacting drug discovery and development. 🚀

Scientific Contributions

Dr. Hui Xiao 🎓 is a leading expert in protein-ligand interactions, structural proteomics, and therapeutic protein analysis 🔬. His pioneering work includes the application of hydrogen-deuterium exchange mass spectrometry (HDX-MS) for epitope mapping 🧩 and microtubule stabilization research. With a deep focus on drug characterization and regulatory sciences, his contributions have significantly advanced biopharmaceutical development 💊. His expertise in mass spectrometry-driven protein analysis has helped enhance the understanding of molecular mechanisms, improving therapeutic strategies. Through innovation and research, Dr. Xiao continues to play a vital role in shaping the future of biopharmaceutical science and drug discovery. 🚀

Potential Considerations

Dr. Hui Xiao 🎓 is a renowned expert in analytical and protein chemistry, with groundbreaking work in epitope mapping and protein characterization 🔬. While his contributions significantly impact drug development, the Pharmaceutical Innovation Achievement Award 🏆 may prioritize direct advancements in drug discovery and novel pharmaceutical interventions 💊. His research has important regulatory and therapeutic implications, but highlighting specific drug innovations or regulatory breakthroughs he has led would further strengthen his case. By showcasing his role in pioneering pharmaceutical advancements, Dr. Xiao’s influence in shaping modern biopharmaceutical science can be fully recognized and appreciated. 🚀

Research Focus

Dr. Hui Xiao’s research primarily focuses on analytical chemistry 🧪, particularly in the quantitative analysis of biomolecules 🧬 using advanced mass spectrometry techniques ⚖️. His work involves CRISPR sgRNA modification analysis 🧬🔬 and the development of LC-MS-based assays for biological therapeutics 💊. He specializes in phosphorothioate isomer detection 🔄 and liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) 📊 for precise biomolecular quantification. His contributions are crucial in drug discovery 🏥, gene editing 🧬, and biopharmaceutical development 💉. His expertise bridges biotechnology 🔬 and analytical methodologies 📈, advancing innovations in therapeutic monitoring and molecular diagnostics 🏥.

Publication Top Notes

Quantitative Analysis of Phosphorothioate Isomers in CRISPR sgRNA at Single-Residue Resolution Using Endonuclease Digestion Coupled with Liquid Chromatography Cyclic Ion Mobility Mass Spectrometry (LC/cIMS)

Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum

Dr. Michel Fares|Drug analysis|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Michel Fares|Drug analysis|Best Researcher Award

Dr. Michel Fares at Nahda University,Egypt

PROFILE  

scopus

Orcid

Google scholar

 

 

Early Academic Pursuits 📚

Michel Yousry Fares embarked on his academic journey with a strong foundation in pharmaceutical sciences, receiving his Bachelor of Pharmacy degree from Nahda University in Beni Suef, Egypt, in 2013. Graduating with honors and a high GPA of 3.89, he demonstrated an early commitment to excellence in his field. His passion for analytical chemistry led him to pursue a Master’s degree in Pharmaceutical Analytical Chemistry at Beni Suef University, where he further honed his skills and knowledge. In 2022, Michel earned his Ph.D. in Pharmaceutical Analytical Chemistry from Cairo University, solidifying his expertise in the analytical methods used to assess pharmaceutical compounds.

Professional Endeavors 🏫

Currently, Michel serves as a Lecturer in the Pharmaceutical Analytical Chemistry Department at Nahda University’s Faculty of Pharmacy, a position he has held since 2022. In this role, he teaches a variety of undergraduate courses, including Pharmaceutical Analytical Chemistry, Instrumental Analysis, and Quality Control of Pharmaceuticals. His responsibilities also extend to research activities in the field of analytical chemistry, where he contributes to advancing the understanding and application of various analytical techniques, such as chromatography and spectroscopy. Michel also plays a key role in mentoring and advising students, helping shape the future of aspiring pharmaceutical professionals.

Beyond his teaching responsibilities, Michel serves as the Vice President of Electronic Learning Support (ELS) at Nahda University, where he has been instrumental in developing and maintaining the university’s e-learning platform, Moodle. His efforts in training instructors and resolving technical issues have significantly enhanced the educational experience for both faculty and students at the university.

Contributions and Research Focus 🔬

Michel’s primary research interests lie in the field of pharmaceutical analytical chemistry, with a specific focus on drug analysis, bioanalysis, and the development of innovative analytical techniques. He has authored several research articles and reviews, including a prominent piece on miniaturized solid-phase extraction techniques for analyzing various pollutants. This work highlights his commitment to advancing analytical methods for environmental and pharmaceutical applications.

His research endeavors also extend to the study of pharmacokinetic parameters, quality assurance, and experimental design. By applying a range of analytical techniques, Michel contributes to improving the quality and safety of pharmaceutical products. His focus on practical applications of pharmaceutical analysis aims to bridge the gap between theoretical knowledge and real-world problem-solving in the pharmaceutical industry.

Accolades and Recognition 🏅

Michel’s contributions to both research and education have not gone unnoticed. He was honored with the “Best Research Publishing Record in the Teaching Assistant Category” in 2022 at Nahda University, a testament to his dedication to advancing scientific knowledge. In 2021, he received the “Best Scientific Research in the Field of Applied Pharmaceutical Sciences” award from ACDIMA (The Arab Company for Drug Industries and Medical Appliances), further cementing his reputation as a leading figure in his field.

Michel’s contributions extend beyond the classroom and laboratory, as he has been actively involved in organizing and participating in scientific conferences. Notably, he was a key participant in the 3rd International Conference of the Faculty of Pharmacy at Ain Shams University and the 2nd International Conference of Pharmaceutical & Therapeutical Science in 2023, where he presented on topics such as online education and creativity in analytical chemistry.

Impact and Influence 🌍

Through his work in both academia and research, Michel has had a profound impact on the field of pharmaceutical sciences. His innovative research has contributed to the development of more efficient and accurate analytical methods, particularly in drug analysis and bioanalysis. As a teacher, he has shaped the careers of many future pharmacists and analytical chemists, emphasizing the importance of precision and quality in pharmaceutical testing.

Michel’s influence extends beyond his direct teaching and research contributions. He has been a reviewer for several prestigious scientific journals, including TrAC Trends in Analytical Chemistry and Journal of Pharmaceutical and Biomedical Analysis, where his expertise helps shape the direction of future research in the field.

Legacy and Future Contributions 🌱

Michel’s legacy is one of dedication to the advancement of pharmaceutical sciences and the education of the next generation of professionals. His work in the development of analytical techniques has had a lasting impact on both the academic and pharmaceutical industries, and his commitment to improving the quality of education will continue to benefit students for years to come.

Looking forward, Michel plans to continue his research into novel analytical methods, with a focus on environmental applications and the use of cutting-edge technologies like electrochemistry and chromatography. His goal is to contribute to the development of sustainable practices within pharmaceutical analysis, ensuring that future generations of scientists have the tools they need to meet the evolving challenges of the global pharmaceutical industry.

In addition to his research, Michel is committed to furthering his role in educational leadership, particularly in the integration of digital technologies into the learning process. He envisions a future where e-learning systems are more widely adopted, creating a more accessible and flexible learning environment for students around the world.

Conclusion ✨

Michel Yousry Fares stands out as a dedicated educator, researcher, and leader in the field of pharmaceutical analytical chemistry. His career is characterized by his commitment to excellence in both teaching and research, his impact on the development of analytical methods, and his dedication to shaping the future of pharmaceutical sciences. Through his ongoing work, Michel will continue to leave a positive and lasting legacy in the field, inspiring future generations of scientists and educators.

🎓Publication 

Green analytical chemistry as an integral part of sustainable education development

  • Authors   : Justyna Płotka-Wasylka, Heba M Mohamed, Aleksandra Kurowska-Susdorf, Rajkumar Dewani, Michel Y Fares, Vasil Andruch
  • Journal    :Current Opinion in Green and Sustainable Chemistry
  • Year         :2021

Determination of the abused intravenously self-administered madness drops (Tropicamide) by liquid chromatography in rat plasma; an application to pharmacokinetic study and …

  • Authors   : Maha M Abdelrahman, Nada S Abdelwahab, Maha A Hegazy, Michel Y Fares, Ghada M EL-Sayed
  • Journal    : Microchemical Journal
  • Year         :2020

Determination of sofosbuvir with two co-administered drugs; paracetamol and DL-methionine by two chromatographic methods. Application to a pharmacokinetic study

  • Authors   :Michel Y Fares, Nada S Abdelwahab, Maha M Abdelrahman, Hamdy M Abdel-Rahman
  • Journal    : Bioanalysis
  • Year         :2019

Miniaturized solid phase extraction techniques for different kind of pollutants analysis: state of the art and future perspectives–PART 1

  • Authors   : Justyna Płotka-Wasylka, Natalia Jatkowska, Monika Paszkiewicz, Magda Caban, Michel Y Fares, Aysegul Dogan, Salvador Garrigues, Natalia Manousi, Natasa Kalogiouri, Paweł Mateusz Nowak, Victoria F Samanidou, Miguel de la Guardia
  • Journal    :TrAC Trends in Analytical Chemistry
  • Year         :2023

Quality by design approach for green HPLC method development for simultaneous analysis of two thalassemia drugs in biological fluid with pharmacokinetic study

  • Authors   : Michel Y Fares, Maha A Hegazy, Ghada M El-Sayed, Maha M Abdelrahman, Nada S Abdelwahab
  • Journal    :RSC advances
  • Year         :2022

Dr.Alice Bejjan| Pharmaceutical Analysis| Women Researcher Award

Published on by Top Pharmaceutical

Dr.Alice Bejjan,Pharmaceutical Analysis ,Women Researcher Award

Dr.Alice Bejjan, at ational Council for Scientific Research of Lebanon-Lebanese Atomic Energy Commission, Lebanon

 Profiles

Scopus

Google scholar         

Orcid

🎓Early Academic Pursuits :

Alice Bejjani’s journey into the world of physics began with a solid academic foundation. She pursued her undergraduate studies at the Lebanese University, Department of Physics and Electronics in Fanar, Lebanon, where she earned her Maitrise in Physics with high distinction in 2003. Her passion for materials science and electronic components led her to continue her studies at the Lebanese University, Faculty of Sciences. There, she obtained a Master of Advanced Studies (DEA) in 2004, once again graduating with high distinction. Alice’s academic pursuits culminated in a Ph.D. in Physics from the Claude Bernard University of Lyon, Institute of Nuclear Physics, France, in 2009, where she achieved the highest honors.

🏢Professional Endeavors :

Alice’s professional career is marked by her extensive contributions to the Lebanese Atomic Energy Commission-National Council for Scientific Research (LAEC-NCSR). She began her journey as a part-time research assistant at the Accelerator Laboratory of LAEC-NCSR in 2004-2005. Following her Ph.D., she returned to LAEC-NCSR as a part-time researcher, equivalent to a post-doctoral position, from 2010 to 2014. During this time, she played a pivotal role in establishing the first research laboratory in the MENA region for surface, chemical, and structural analysis of solid materials using the Time of Flight Secondary Ion Mass Spectrometry (TOF-SIMS) technique.

In 2014, Alice was appointed as a full-time researcher at LAEC-NCSR, a position she held until 2019. Her research interests include exploring novel applications, developing innovative protocols, and combining ion beam technology with optical spectroscopic and chromatography methods to examine materials pertinent to health, environmental studies, and forensic sciences. Since 2019, she has been serving as a senior researcher, furthering her contributions to the field.

🔬Contributions and Research Focus :

Alice’s research has had a profound impact on the fields of health, environmental studies, and forensic sciences. As the coordinator of the Forensic Research Program at LAEC-NCSR since 2016, she has fostered synergy among her fellow researchers to achieve program objectives. She has designed and implemented Memorandums of Understanding (MOUs) with partners, driving impactful advancements in forensic research.

As the principal investigator of the TOF-SIMS laboratory, Alice oversees a team of researchers, research assistants, and master’s/Ph.D. students. She has established and enforced standard operating protocols to ensure compliance with safety and regulatory guidelines, maintained the laboratory’s cutting-edge status through equipment procurement and technology advancements, and implemented preventive maintenance plans to ensure optimal functionality and efficiency. Her efforts have also included fostering collaborations with local and international universities and research centers.

 🏆Accolades and Recognition :

Alice’s dedication and contributions to science have been recognized through various national and international grants. Notable among these are:

  1. TC-IAEA Grant (2022-2025): €405,000 for strengthening forensic needs in material investigation.
  2. NCSR National Grant (2018-2019): $19,000 for multi-dimensional analysis of new functional polymers.
  3. NCR Italy-NCSR Mobility Grant (2017-2019): €8,000 for safeguarding saffron authenticity using innovative mass spectrometry.
  4. TC-IAEA Grant (2015-2018): €350,000 for enhancing forensic science capabilities.
  5. TC-IAEA Grant (2012-2014): €350,000 for upgrading surface, elemental, and structural analysis capabilities.
  6. TC-IAEA Grant (2010-2012): €522,000 for enhancing the LAEC’s analytical capabilities.

🌟Impact and Influence :

Alice’s work has had a significant impact on the scientific community and beyond. Her research has contributed to advancements in forensic science, health, and environmental studies. By developing innovative protocols and combining ion beam technology with other analytical methods, she has opened new avenues for material analysis. Her leadership in establishing and maintaining the TOF-SIMS laboratory has provided valuable resources for researchers in the MENA region and internationally.

🌍Legacy and Future Contributions :

Alice Bejjani’s legacy is one of dedication, innovation, and collaboration. Her contributions to the scientific community, particularly in the fields of forensic science and material analysis, have set a high standard for future researchers. As she continues her work at LAEC-NCSR, she is poised to make further advancements in her field, fostering interdisciplinary collaboration and driving impactful research. Her commitment to mentoring the next generation of scientists ensures that her influence will continue to be felt for years to come. Alice’s journey is a testament to the power of perseverance, passion, and the pursuit of excellence in science.

🎓Publication 

Fe0-based trimetallic systems for the removal of aqueous diclofenac: Mechanism and kinetics

  • Authors   :Antoine Ghauch, Hala Abou Assi, Habib Baydoun, Al Muthanna Tuqan, Alice Bejjani
  • Journal    :Chemical Engineering Journal
  • Year         : 2011

Iron-based metal organic framework MIL-88-A for the degradation of naproxen in water through persulfate activation

    • Authors : Rime El Asmar, Abbas Baalbaki, Zahraa Abou Khalil, Sahar Naim, Alice Bejjani, Antoine Ghauch
    • Journal   :Chemical Engineering Journal
    • Year       : 2011
Toward cell selective surfaces: cell adhesion and proliferation on breath figures with antifouling surface chemistry
  • Authors  : Enrique Martínez-Campos, Tamara Elzein, Alice Bejjani, Maria Jesús García-Granda, Ana Santos-Coquillat, Viviana Ramos, Alexandra Muñoz-Bonilla, Juan Rodríguez-Hernández
  • Journal    :ACS Applied Materials & Interfaces
  • Year         :  2016
Hydrophobization of chitosan films by surface grafting with fluorinated polymer brushes
  • Authors  : Bénédicte Lepoittevin, Tamara Elzein, Diana Dragoe, Alice Bejjani, Frédéric Lemée, Jocelyne Levillain, Philippe Bazin, Philippe Roger, Isabelle Dez
  • Journal   :Carbohydrate polymers
  • Year        :   2019

Surface initiated supplemental activator and reducing agent atom transfer radical polymerization (SI-SARA-ATRP) of 4-vinylpyridine on poly (ethylene terephthalate)

  • Authors  : Mohamad Maaz, Tamara Elzein, Alice Bejjani, Nadine Barroca-Aubry, Bénédicte Lepoittevin, Diana Dragoe, Sandra Mazerat, Bilal Nsouli, Philippe Roger
  • Journal   :Journal of colloid and interface science
  • Year        : 2017